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Abstract
An important goal of research involving gene expression data for outcome prediction is to establish
the ability of genomic data to deﬁne clinically relevant risk factors. Recent studies have demonstrated
that microarray data can successfully cluster patients into low- and high-risk categories. However, the
need exists for models which examine how genomic predictors interact with existing clinical factors and
provide personalized outcome predictions. We have developed clinico-genomic tree models for survival
outcomes which use recursive partitioning to subdivide the current data set into homogeneous subgroups of
patients, each with a speciﬁc Weibull survival distribution. These trees can provide personalized predictive
distributions of the probability of survival for individuals of interest. Our strategy is to ﬁt multiple models;
within each model we adopt a prior on the Weibull scale parameter and update this prior via Empirical
Bayes whenever the sample is split at a given node. The decision to split is based on a Bayes factor
criterion. The resulting trees are weighted according to their relative likelihood values and predictions
are made by averaging over models. In a pilot study of survival in advanced stage ovarian cancer we
demonstrate that clinical and genomic data are complementary sources of information relevant to survival,
and we use the exploratory nature of the trees to identify potential genomic biomarkers worthy of further
study.
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1. Introduction
Genomic information, in the form of microarray or gene expression signatures, has an
established capacity to deﬁne clinically relevant risk factors in disease prognosis. Recent studies
have generated such signatures related to disease recurrence and survival in ovarian cancer
[62,2] as well as in numerous other disease contexts [72,58,48]. Analyses involving gene
expression signatures have focused on clustering or classiﬁcation to associate such signatures or
patterns with ‘low-risk’ versus ‘high-risk’ survival prognoses. The clustering of tumors based on
expression levels into multiple subgroups has been performed using various methods including
support vector machines [72], k-NN models [62], PLS [45] and hierarchical clustering [47].
A more formal discussion and comparison of various tumor discrimination methods with gene
expression data can be found in [19].
The application of gene expression signatures to the prediction of disease outcome is a
research area distinct from clustering applications. Less attention has been focused on prediction
to date, although single genes or gene signatures have been studied for the prediction of tumor
classiﬁcation related to ‘good’ versus ‘poor’ survival prognoses [70,21]. However, the ‘signature’
approaches to prediction of cancer outcome with microarrays have been shown to be highly
unstable and strongly dependent on the selection of patients in the training sets [43]. This has
been attributed to inadequate validation leading to overoptimistic results, but also reﬂects the
heterogeneity of complex disease. From the perspective of the individual patient a sharper, more
specialized approach to prediction is needed.
Bayesian regression tree models, described in Section 2, form the basis of one such approach.
The conventional binary regression tree associated with CART [9] has been used successfully
for prediction in various modeling contexts [5,63] as have the Bayesian versions of CART [12,
16], other Bayesian binary trees [49], and the relative risk trees of Ishwaran, Blackstone, Pothier,
and Lauer [32]. A review of tree-based methods for survival can be found in [73]. Research has
shown that the prediction accuracy of such models can be improved through Bayesian model
averaging [25], bagging [5], boosting [60], and related methods [13]. This holds true for trees
whether the model search is stochastic [67,7,35] or deterministic [10,44]. Our approach is a
reﬂection of this ﬁnding and of the recent emphasis in the literature on ensemble methods for
prediction [14,26,27]. A key aspect in our approach is the averaging of predictions over multiple
candidate models, which we discuss in Section 3. Note that Bayesian model averaging not only
improves predictive performance but the posterior parameter estimates and standard deviations
directly incorporate model uncertainty [51].
In this article we discuss the development of Bayesian tree models that allow the use
of clinical, histopathological, and genomic data in the prediction of disease-related survival
outcomes. These regression tree models have ability to discover and evaluate interactions of
multiple predictor variables, and deﬁne ﬂexible, non-linear predictive tools [49]. Speciﬁcally, our
method allows the direct evaluation of the relative importance of clinical and genomic predictors.
Our approach is demonstrated in the context of prediction of survival after surgery for ovarian
cancer patients. We stress the utility of such tree models in the exploration of genomic data, and
the resulting identiﬁcation of genes plausibly associated with clinical endpoints, as well as for
prediction.
2. Regression trees
Our focus is the development of regression trees that recursively generate binary partitions of
the covariate space, based upon speciﬁc clinical and genomic variables, and within each partition
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accuratelymodelacontinuoussurvivaltimeresponsevariable.Onekeyadvantageofsuchtreesis
their interpretability: the entire feature space can be explained by a single tree and the prediction
for any given individual can be interpreted as a conjunction of simple logical expressions [17,
24]. Regression tree models serve as tools for prediction as well as for exploratory data analysis
by discovering simple combinations of covariates that correlate with a particular outcome. In the
case of genomic data these combinations can then serve as a basis for further biological study.
Recent additions to the survival tree modeling literature, including [26,27] and [33], reﬂect the
importance of survival trees as an analytic technique for data sets with complex structure.
In the remainder of this section we discuss model construction and model inference. We
begin with a brief overview of recursive partitioning models (Section 2.1) and the use of the
Exponential and Weibull distributions to model the conditional distribution of the response
variable (Section 2.3). Then we discuss the splitting criterion based on Bayes factors and
inference via Empirical Bayes methods (Section 2.2) and posterior distributions and predictive
distributions (Section 2.4). The generation of predictive distributions by model averaging is
discussed in Section 3. Although our models can be applied to censored data (under the
assumption of non-informative censoring) [15,48], we conﬁne our discussion to the fully
observed case.
2.1. Recursive partitioning
We assume a continuous survival time response variable Y and a p-dimensional vector of
covariates X. Each covariate X j, j = 1,..., p, may be categorical or continuous. We assume
that the distribution of Y|X can be expressed as Y|g(X) where g is a recursive binary partitioning
or splitting of the covariate space into disjoint subspaces. Each binary split is deﬁned by a rule
which assigns an observation in the current partition to one of two partition subspaces based
upon a predictor X j and a threshold value τ. The choice of the pair (X j,τ) is made by ﬁnding
the pair which reorganizes the data in the current partition into two subgroups whose survival
distributions are most different, as assessed by a splitting criterion (see Section 2.2.1). A split
is performed if the value of this criterion exceeds a speciﬁed threshold of signiﬁcance. This
splitting process continues in a recursive fashion until the existing model cannot be improved.
The result is a tree model M(Y,X) in which the terminal nodes or leaves represent a partition of
the covariate space in which the distribution of Y is distinct.
For a given node and predictor it is possible that any of several threshold values would yield
a signiﬁcant split. The ability to generate multiple trees at a node may be advantageous. In
problems with many predictors, this naturally leads to the generation of many trees, often with
small changes from one to the next, and the consequent need to develop inference and prediction
in the context of multiple trees generated this way. The use of ‘forests of trees’ and similar
ensemble methods has been urged by Breiman [8] as well as others [26] and our perspective
endorses this. The involvement of multiple trees in our analyses is supported by the viewpoint
that the splitting of nodes is based on the selection of (predictor, threshold) pairs which we view
as parameters of the overall tree model. Any single tree is formed by selecting speciﬁc values
for these parameters and the uncertainty in these parameters is reﬂected in the variability among
trees. The resulting models generate predictions via model averaging. This process is discussed
in more detail in the following Section and in Section 3.
2.2. Tree generation
We employ a forward-selection process to generate tree models. If the data in a node of a
single tree is a candidate for splitting, we ﬁnd the (predictor,threshold) pair that maximizes the
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splitting criterion (see below) for a split at the given node. The node is split if the value of this
criterion is sufﬁciently large. Given a current tree the splitting process continues until either the
existing model cannot be improved, i.e., the splitting criterion is not sufﬁciently large for any
choice of (predictor,threshold) at any node, or until all of the remaining candidate terminal nodes
have very few observations (usually less than 5 observed survival times). Our strategy is unlike
other tree-growing methods (including CART), which purposely overgrow a tree and then prune
back, due primarily to our focus on prediction in settings of low signal to noise. We want to
limit adaptivity and avoid overﬁtting, at the possible cost of missing an association of moderate
signiﬁcance.
2.2.1. Bayes factors
The choice of splitting criterion is based on the association between the outcome variable Y
(survival time) and the covariates X in subsamples. Splitting variables and splitting thresholds are
selected based on their ability to strengthen this association. With data y1,..., yn in a given node
and a speciﬁed threshold τ on a given predictor x j, our test of association is based on assessing
whether the data are more consistent with a single exponential distribution (with exponential
parameter µτ) or with two separate exponential distributions (with parameters µ0,τ and µ1,τ)
deﬁned by the speciﬁed partition.
In our Bayesian approach we adopt the standard conjugate Gamma prior model on the
Exponential parameter [61]; the prior is Gamma(a,b) where b = a/m and m is the mean of the
Gamma prior. We specify a ﬁxed global prior mean but treat the scale parameter a as uncertain
and node speciﬁc; a is estimated via Empirical Bayes (EB). In brief, suppose a node has rz
individuals with observed survival times and Yz is the sum of all survival times (here z = 0,1
identiﬁes the node as one of two children nodes of a parent node). Assuming µ0,τ 6= µ1,τ we
take µ0,τ and µ1,τ to be independent with common prior Gamma(aτ,bτ) with mean aτ/bτ.
Under the null hypothesis µ0,τ = µ1,τ the common value has the same Gamma prior. Let
the parameters of the current prior Gamma(aτ,bτ) be expressed as aτ = cτ and bτ = cτ/m
where m is the prior mean. The empirical Bayes approximation to µz,τ | (rz,Yz,µ|1−z|,τ) is
Gamma(cτ+rz,(cτ/ˆ µz,τ)+Yz) where ˆ µz,τ is the marginal maximum likelihood estimate (MLE)
(found iteratively). The updated prior will serve as the prior on µz,τ and the EB estimate of a will
be used in the splitting criterion. This has two key aspects: ﬁrst, it permits ‘borrowing strength’
across the two subgroups or children nodes to estimate this key parameter; second, it allows
for differing prior Gamma shape parameters at different nodes in each tree, thus it is ﬂexible in
responding to varying degrees of uncertainty as we move down the tree.
A candidate split of a given node will organize the data as follows:
nobs
P
i Yi
xj ≤ τ r0 Y0 n0
xj > τ r1 Y1 n1
r Y
where nz is the total number of survival times in subgroup z (in the uncensored case rz = nz).
The splitting criterion or test of association is based on assessing the Bayes factor Bτ [37]
comparing the null hypothesis H0 : µ0,τ = µ1,τ (with common value µτ) with the alternative
H1 : µ0,τ 6= µ1,τ. The Bayes factor Bτ in favor of the alternative over the null hypothesis is
simply
Bτ =
Γ(aτ + r0)Γ(aτ + r1)
Γ(aτ)Γ(aτ + r)
b
aτ
τ (bτ + y)aτ+r
(bτ + y0)aτ+r0(bτ + y1)aτ+r1 .
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The Bayes factor is calibrated to the likelihood-ratio scale. However, it will provide more
conservative estimates of signiﬁcance than both likelihood-based approaches and more
traditional signiﬁcance tests [57]. The Bayes factor will naturally choose smaller models over
more complex ones if the quality of ﬁt is comparable and hence provide a control on the size of
our trees [3].
In comparing predictors the Bayes factor can be evaluated for each predictor across a range
of predictor-speciﬁc thresholds. For a given predictor this generates values of Bτ as a function of
τ, which may suggest promising threshold values.
2.3. Weibull transformation
Suppose that a node of a given tree is to be split on a predictor x j at the (threshold) value τ.
Let yzi and rz be as deﬁned in Section 2.2.1 where i denotes the ith individual in subgroup z,
i = 1,...,nz, and yzi ∼ Exp(µz,τ). The data density is
p(yz | µz,τ,rz) = µ
rz
z,τe
−µz,τ
nz P
i=1
yzi
.
A careful examination of data from earlier studies of survival and cancer [2,15] revealed that the
survival distribution could be more accurately represented by a Weibull distribution. The Weibull
may be not only the most widely used parametric survival model but with its shape parameter it
can be viewed as a generalization of the Exponential [30]. We subsequently denote the survival
time as tz where tz has a Weibull distribution with parameters µz,τ and α. If tzi is the survival
time for individual i from subgroup z then
p(tzi | µz,τ,rz,α) = αµz,τtα−1
zi e−µz,τtα
zi
for i = 1,...,nz,z = 0,1. Note that the Weibull distribution is a power transformation of the
Exponential distribution (yzi = tα
zi). For a speciﬁed, global Weibull shape parameter α, we can
transform the data to Exponential, analyze the data and build trees with Exponential survival
distributions, and then transform back to the original scale for predictions of new cases.
In our parameterization of the Weibull the scale parameter has been incorporated into the
deﬁnition of µz,τ. As the value of µz,τ varies across different nodes of a tree so does the scale
parameter. Since the splitting criterion for the trees is based on a signiﬁcance test of the value
of µz,τ, the scale parameter is implicitly, although not directly, incorporated into the splitting
criterion and hence used for growing the tree. The current model could be reparameterized to
address the scale parameter directly; however, this would require an entirely different Bayesian
analysis as the interpretation of µz,τ is essential to the current conjugate analysis (see [61]).
2.4. Inference and prediction
Inference and prediction at a terminal node or leaf of a given tree involve the calculation
of branch probabilities and the posterior predictive distributions which underlie the predictive
probabilities for new cases. To calculate the branch probabilities for a leaf we must follow the
path or sequence of nodes of the tree that connect the root node with the speciﬁed leaf.
We consider the kth node of the tree and suppose that it is split on the pair (x jk,τjk), where
the notation of Section 2.2 has been extended to include the node index. The data in node k
can be divided into two groups based on the values of (x j,τj), where the sums of all of the
survival times in the x j ≤ τj and x j > τj groups are Y0k and Y1k, respectively. The implied
conditional probabilities P(Yzki > t | Z = z),i = 1,...,nzk, for some time t are the branch
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probabilities deﬁned by this split (the dependence of these probabilities on the tree and the data
are suppressed for clarity). From Sections 2.2 and 2.3 we know that these probabilities are based
on Exponential distributions for yzki with parameter µz,τjk for z = 0,1 and speciﬁed Gamma
priors which we index by the parent node, i.e., Gamma(aτjk,bτjk). The use of EB to estimate
aτjk has been described in Section 2.2 and will not be discussed here. Assuming that node k
is split, the resulting conditional posterior branch probability parameters would be independent
with posterior Gamma distributions:
µ0,τjk ∼ Gamma(aτjk + r0j,bτjk + y0j) and µ1,τjk ∼ Gamma(aτjk + r1j,bτjk + y1j).
These distributions allow inference on the branch probabilities and play an essential role in
predictive calculations, as we now describe.
Let x? be an observed vector of covariates for a new case and consider predicting the response
P(y? > t | x?) for a given time t. The current tree will deﬁne a single path for this observation
from the root node to a terminal node or leaf. Prediction requires that we follow x? along its path
down the tree to the implied leaf and construct the relevant posterior deﬁned by the (x,τ) pairs
at the splits that we encounter along the path. For example, suppose that our new case x? has an
implied path through nodes 1 and 2 terminating at node 5 (a leaf), where each tree split deﬁnes
exactly 2 children nodes (node numbers increase from left to right within levels starting with the
root node as node 1). This path is based on (predictor, threshold) pairs (x1,τ1) and (x2,τ2) and
is a result of predictor values (x?
1 ≤ τ1) and (x?
2 > τ2). After the root split the parameter of
the Exponential distribution of the survival times in node 2 has a posterior Gamma distribution,
i.e., µ0,τ1,1 ∼ Gamma(aτ1,1 + r01,bτ1,1 + y01).
The prior parameters aτ1,1 and bτ1,1 are updated via empirical Bayes using r01 and y01
resulting in aτ2,2 and bτ2,2. The split of node 2 would lead to a posterior Gamma distribution
for the parameter of the Exponential distribution of the survival times in node 5, i.e., µ1,τ2,2 ∼
Gamma(aτ2,2 +r12,bτ2,2 +y12). For notational simplicity, let µ1,τ2,2, aτ2,2 +r12, and bτ2,2 +y12
be denoted by µ5, a5 and b5, respectively. The prediction of the response P(y? > t | x?) involves
the posterior predictive distribution of future survival times for cases in node 5, i.e.,
P(y? > t | x?) =
b
a5
5
Γ(a5)
Z ∞
0
µ
(a5−1)
5 e−µ5(t+b5)dµ5 =
b
a5
5
Γ(a5)
Γ(a5)
(b5 + t)a5 =

b5
b5 + t
a5
which is a Gamma mixture of exponentials, or a Pareto distribution of the second kind
(P(I I)(0,b5,a5)) [34].
Prediction follows by estimating P(y? > t | x?) based on the sequence of conditionally-
independent posterior distributions for the branch probabilities that deﬁne it. Simply plugging in
the posterior conditional means of each µz,τ,j will lead to a plug-in estimate of P(y? > t | x?).
Since each exponential mean follows a Gamma posterior, it is possible to draw Monte Carlo
samples of the µz,τ,j and compute the corresponding values of P(y? > t | x?) to generate a
posterior sample for summarization. In this way we can examine the simulation-based posterior
means and uncertainty intervals for P(y? > t | x?) which represent predictions of the survival
probabilities for the new case.
3. Generation and weighing of multiple trees
The use of forests of trees and similar ensemble methods has been urged by Breiman [8] as
well as others [44,26] as previously noted. In our analyses the (predictor,threshold) pairs are
viewed as parameters of the overall tree model. Statistical learning about relevant trees requires
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the examination of aspects of the posterior distributions of these parameters (and of the branch
probabilities). Our Bayesian approach to survival tree modeling allows us to properly address
model uncertainty, as has been done in similar contexts by others [10,16,12].
Trees are known as unstable classiﬁers [9]; however predictions may be improved by selecting
a group of models instead of a single model and generating predictions by model averaging, as
in [10,25]. Copies of the ‘current’ tree are made and the current node is split on a different
signiﬁcant (predictor,threshold) choice for each copy. Once a number of trees have been
generated we can involve all or some of them in inference and prediction by weighting the
contribution of each tree by its relative likelihood value. As a result of the current framework
of forward generation of trees the likelihood values are easy to compute. For any single tree
the overall marginal likelihood can be calculated by identifying the nodes which have been split
and taking the product of the component marginal likelihoods deﬁned by each split node. In other
words (using the notation of Section 2.4) the marginal likelihood component deﬁned by node k is
mk =
Z ∞
0
Y
z=0,1
p(yzk | µz,τjk,rzk,τjk)p(µz,τjk)dµz,τjk
where µz,τjk is the Gamma(aτjk,bτjk) prior for each z = 0,1. We simplify this to
m j =
Y
z=0,1
b
aτjk
τjk Γ(aτjk + rzk)
(bτjk + yzk)
(aτjk+rzk)Γ(aτjk)
.
The product of the component marginal likelihood values over all such split nodes k is the over-
all marginal likelihood value for the tree. This value is relative to the overall marginal likelihood
values of all of the trees generated, which can be normalized to provide relative posterior proba-
bilities for the trees based on an assumed uniform prior. These probabilities are valuable for both
tree assessment and as relative weights in calculating average predictions for future observations.
To represent predictions across many candidate trees, we use simulation: sample a tree model ac-
cording to the posterior probabilities, i.e., the normalized relative likelihoods, then sample the
implied unique Pareto distribution for a candidate future sample, based on the predictor proﬁle
of that case, in the chosen tree. Repeating this leads to a Monte Carlo sample from the predictive
distribution that represents both within-tree uncertainties and, potentially critically, uncertainty
across tree models. These samples can be summarized to produce point and interval estimates of
survival probabilities at any chosen set of time points, and proﬁles of the full predicted survival
distributions.
4. Sensitivity and performance on simulated data
Like any method for statistical inference our modeling approach and results will depend on
various assumptions. These include the choice of prior and the data likelihood. In this section
we consider the sensitivity of our method to the assumed value of the Weibull shape parameter α
(see Section 2.3) in a predictive context using simulated data. To aid in determining whether our
method behaves as expected, we employ two other modeling approaches for comparison. Our
hope is that this assessment, although limited, will provide useful information concerning the
strengths and weaknesses of our approach.
4.1. Setup
Our setup is similar to that of Hothorn et al. [28]. Five independent predictors X1, X2,..., X5
were generated from a uniform distribution on [0,1]. Survival times were generated from a
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Fig. 1. Median MIE values (with 95% error bars) from model A simulation with Weibull shape parameter = 0.8. The
two y-axes indicate median MIE value (left) and percent improvement over Kaplan–Meier (right).
Exponential distribution with conditional survival function S(y|x) = exp(−yµx) under three
models with logarithms of the hazards (A) log(µx) = 0, (B) log(µx) = 3I(X1 ≤ 0.5 ∩ X2 >
0.5), or (C) log(µx) = 3X1 + X2. These times were then transformed to follow a Weibull
distribution with shape parameter α; values of α were [0.5,0.8,1.0,1.2,1.5].
The behavior of our models was compared to both a simple Kaplan–Meier curve and survival
trees as implemented in the rpart package [66] in the R system for statistical computing [50].
Comparison to proportional hazards has been presented elsewhere [15]. The parameters for the
rpart routine were set as in [28]. For our tree models the maximum number of trees allowed was
30, the minimum Bayes factor value required for a split was 2.5, and only nodes containing at
least 3 observations were candidates for splitting. Numerous parameter combinations were tried
with minimal impact on the results, if any. Trees with normalized likelihood values below 5%
wereremovedfromconsideration.Themeanintegratedsquarederrorwasemployedasameasure
of the quality of the model predictions (computed by numerical integration). The learning sample
contained 200 observations and the value of the predictions was evaluated on an independent
sample of 100 observations.
4.2. Results
We have selected three representative runs to discuss: model A at α = 0.8, model B at
α = 1.2, and model C at α = 1.5. Within each run the value of α assumed by the Weibull
tree models (which we will refer to as αﬁx) takes each value from the set [0.5,0.8,1.0,1.2,1.5].
The median MIE result and the 95% conﬁdence interval for the median MIE calculated for
100 replications of the learning and evaluation sets for these runs are displayed in Figs. 1–3.
For model A the Weibull tree performs best at values of αﬁx near the true α. As expected, the
error increases as αﬁx moves away from α but the performance of the trees does not degrade
notably until αﬁx  1. Note that α = 1 is the transition point for the monotonicity of the hazard
function (the hazard is decreasing for α < 1 and increasing for α > 1). The Weibull method
was able to capture the correct (null) model in all runs across αﬁx values; however the number
of trees selected increased as αﬁx  1 (from an average of 1 tree selected to an average of 1.25
Please cite this article in press as: J. Clarke, M. West, Bayesian Weibull tree models for survival analysis of clinico-
genomic data, Statistical Methodology (2007), doi:10.1016/j.stamet.2007.09.003ARTICLE  IN  PRESS
J. Clarke, M. West / Statistical Methodology ( ) – 9
Fig. 2. Median MIE values (with 95% error bars) from model B simulation with Weibull shape parameter = 1.2. The
two y-axes indicate median MIE value (left) and percent improvement over Kaplan–Meier (right).
trees selected). For comparison the rpart method selected the correct (null) model in 91.8% of
runs.
In Fig. 2 the Weibull model performs well for αﬁx > 1 with α = 1.2. For small values of αﬁx
the error and variability of the results increase; this parallels an increase in the number of trees
selected and a decrease from 97% to 71% in the number of runs where the correct model was
selected (the rpart method selected the correct model in 86.6% of runs). Similarly to the results
in Fig. 1 we see a loss of performance for values of αﬁx < 1 where the monotonicity of the
assumed hazard function is opposite to the monotonicity of the true hazard function. This pattern
is also reﬂected in Fig. 3 but with relatively larger error bars. The increase in variability in Fig. 3
is the result of averaging over more trees (an average of 1.58 trees) in an attempt to capture the
linear equation in the log hazard function. Overall the results demonstrate that the Weibull trees
are sensitive to the monotonicity of the assumed hazard function, as reﬂected in the value of αﬁx,
and its correspondence to the monotonicity of the true hazard function.
5. Analysis in ovarian cancer research
Ovarian cancer is the deadliest of the gynecologic cancers and the ﬁfth leading cause of cancer
deathsamongwomentoday[1].Whenmakingovariancancerdiagnosesandprognosesclinicians
rely on subjective interpretations of both clinical and histopathological information, which can be
incomplete or unreliable [62]. Recent studies in ovarian cancer have demonstrated the potential
of genomic data to improve our ability to predict patient survival and treatment response [62,2].
We chose to utilize Weibull trees to explore pilot data collected from 119 advanced stage
ovarian cancer patients treated at either Duke University Medical Center or H. Lee Mofﬁtt
Cancer Center & Research Institute. The primary purpose of this analysis was to determine
whether genomic data could demonstrate ability to predict survival that was not reﬂected in
available clinical data such as disease-free interval (time between primary chemotherapy/disease
relapse and disease recurrence) and, if so, to explore which genes may demonstrate such ability
and whether a larger study would be of interest. Tissue samples were collected at the time of
initial cytoreductive surgery and all patients received primary chemotherapy with a platinum-
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Fig. 3. Median MIE values (with 95% error bars) from model C simulation with Weibull shape parameter = 1.5. The
two y-axes indicate median MIE value (left) and percent improvement over Kaplan–Meier (right).
based regimen (usually including taxane) subsequent to surgery. Detailed clinical records of
traditional risk factors (age, stage, grade, debulking status) and measurement of disease-free
interval were available for 55 of the 119 patients and have been summarized in Table 1. Gene
expression data was generated for each patient at the institution of sample origin from RNA
extracted from banked tissue derived from primary tumor biopsies. This RNA was hybridized to
Affymetrix Human U133A GeneChips according to standard Affymetrix protocol. The results
were expression levels from over 22,000 genes and expressed sequence tags (ESTs) for each
individual. The pre-processing of the gene expression data (normalization and screening) and the
use of dimension reduction techniques to build composite genomic predictors prior to analysis
are discussed in Sections 5.1 and 5.2. The overall survival time (time from diagnosis to patient
death) was selected as the response variable.
TheclinicalcharacteristicsoftheDukeandMofﬁttsampleswerenotcomparable(seeTable1)
and hence we could not use one for training the model and one for validation. We excluded the
possibility of using leave-one-out cross-validation due to its instability in model selection [6]
and decided instead to divide the combined data set of 55 samples into a training set (60% of
samples) and a test set (40% of samples). Although this may introduce bias in internal validation
[52], the primary interest in terms of a possible future study is in external validation. Training and
test sets were balanced for age, array location (Duke or Mofﬁtt), debulking status, and response
to platinum therapy. In order to account for possible assignment bias due to unknown factors we
performed 10 runs; in each run the samples were split into different training and test sets and all
steps of the analysis, including expression data pre-processing, were repeated.
5.1. Pre-processing of expression data
The ovarian cancer data contained expression levels from over 22,000 genes and expressed
sequence tags (ESTs) for each individual. We chose to use GeneChip RMA (GCRMA) as
our measure of expression since it has been shown to balance accuracy and precision [31].
Our expression data were initially screened to exclude genes showing minimal variation across
samples. We evaluated the remaining genes for consistency across both sets using integrative
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Table 1
Ovarian cancer clinical data
Duke Mofﬁtt
N % N %
Age
<45 2 5.7 2 10.0
45–55 8 22.9 5 25.0
55–65 11 31.4 7 35.0
65–75 11 31.4 4 20.0
>=75 3 8.6 2 10.0
Mean/Min/Max 60/33/79 59/33/76
Stage
III 31 88.6 14 70.0
IV 4 11.4 6 30.0
Grade
I 1 2.9 2 10.0
II 15 42.9 3 15.0
III 19 54.3 15 75.0
DFS interval (mo.)
<12 24 68.6 12 60.0
>=12 11 31.4 8 40.0
Mean/Min/Max 20.0/0.0/156.0 12.1/0.0/44.0
Surgical debulking
Suboptimal (>1 cm) 21 60.0 4 20.0
Optimal (<1 cm) 14 40.0 16 80.0
Platinum response
Yes 22 68.9 4 20.0
Partial 8 22.9 16 80.0
No/Stable disease 5 14.3 0 0.0
Survival time (mo.)
Observed 30 85.7 6 30.0
Censored 5 14.3 14 70.0
Mean/Min/Max 55.3/6.0/185.0 39.0/11.0/101.0
DFS = disease-free survival.
correlations as described in [46]. Across different runs an average of 6400 genes passed all
screens (sd = 53.42 genes). Although individual genes could be used as predictors, we chose to
create predictors from clusters of similar genes both to reduce dimension and to identify multiple
underlying patterns of variation across samples.
5.2. Clustering and metagene selection
The evaluation and summarization of large-scale gene expression data in terms of lower
dimensional factors of some form are being increasingly utilized both to reduce dimension
and to characterize the diversity of expression patterns evidenced in the full sample [39,23].
The idea is to extract multiple patterns as candidate predictors while reducing dimension
and multiplicities and smoothing out gene-speciﬁc noise. Discussion of various factor model
approachesappearsin[71].Consideringthenumberofgenesinourdatasetandtheheterogeneity
of the sample patients we ﬁrst applied k-means correlation-based clustering to the genes and
selected the dominant principal component (or metagene [29]) to represent each cluster. These
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Fig. 4. Permutation null distribution (blue) and distribution of gene silhouette values from run 1 (red). (For interpretation
of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
metagene predictors are input to the tree model analysis, along with the clinical predictors, as a
re-expression of the genomic information contained in the original microarray data. Although
k-means was chosen for its ease of use and wide availability our approach is amenable to other
clustering techniques.
The k-means clustering algorithm was applied to the training data in each run, generating an
average of 490 gene clusters (sd = 2.76 clusters). As the true number of clusters is unknown
it was possible that some clusters did not represent subsets of related genes but were simply
an artifact of the clustering algorithm. We identiﬁed such clusters by assessing the silhouette
widths [38] of genes within clusters and removing clusters containing genes whose widths were
not signiﬁcant. This approach is similar to that of Dudoit and Fridlyand [18]. The signiﬁcance
of a width was determined by comparison to a permutation-based null distribution generated by
randomly permuting the entries of each row of the observed gene expression matrix, clustering
this permuted matrix using k-means as above, and calculating the silhouette values for the
permuted genes. Only clusters whose genes had signiﬁcant silhouette values (p < 0.05)
were retained, leaving an average of 310 metagenes for analysis (sd = 20.87 clusters). The
permutation null distribution and the gene silhouette values from the initial training/test run are
displayed in Fig. 4. The silhouette values by cluster size are displayed in Fig. 5.
5.3. Predictive results
Using the training data as a learning set we generated multiple trees under a variety of
parameter settings using clinical predictors only, metagenes only, and both metagenes and
clinical predictors. The parameter settings were as follows: Bayes factor thresholds of 2.0, 2.5,
or 3 on the log base 2 scale, Weibull shape parameter values of 0.8, 1.0, or 1.2, Gamma prior
parameters of α = 2 and β = 1/60 or 1/120, up to 20 splits (i.e., 20 new trees) at the root
node and up to 3 at each second level node. The choice of Bayes factor threshold was based on
frequentist properties: a Bayes factor of 3 is approximately equivalent to a p-value of 0.05.
The Gamma prior parameters were chosen to roughly match the mean of the training data,
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Fig. 5. Gene silhouette values by cluster size from run 1.
i.e., αβ = µ. The Weibull shape parameter is unknown but values were selected based on the
histogram of the training data. Any tree whose relative likelihood value exceeded 1% contributed
to the generation of predictions via model averaging. The combination of parameter settings
which produced the trees with the most accurate ﬁtted values were retained and used to generate
predictions for the validation set. A ﬁtted value at time t for an individual was ‘accurate’ if the
ﬁtted probability of surviving for at least time t was greater than a speciﬁed cutoff if the recorded
survival time for the individual is greater than time t, and vice versa. The speciﬁed cutoff was
based on an ROC curve to balance speciﬁcity and sensitivity. The predictive accuracy of a ﬁtted
model was assessed by calculating the predicted auROC estimates at 3-, 4-, and 5-year survival
endpoints [11].
As can be seen in Table 2 the predictive results varied across the runs with a validation auROC
for the median predictions of the clinical only (C), genomic only (G), and clinico-genomic (CG)
tree models of 78.96%, 81.27%, and 84.28% at 3-year survival; 79.94%, 81.19%, and 83.55% at
4-year survival; and 76.93%, 77.92%, and 81.11% at 5-year survival. For C models an average
of 4 trees had appreciable relative likelihood and contributed to the predictions in any given run.
For the G and CG models the average number of contributing trees was 35 and 36, respectively,
although only an average of 4.2 and 2.4 trees, respectively, had relative likelihoods above 5%.
Note that in several runs the genomic predictors did not improve upon the predictive ability of
the clinical data, and in one run (run #8) none of the models demonstrated the ability to predict,
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Fig. 6. A high likelihood clinico-genomic survival tree; each node contains the (predictor,threshold) which created the
node split, the number of sample individuals in the node, and the posterior predictive probability of 3-year survival for
that subpopulation.
but the additional predictive ability provided by the genomic variables is evident when looking
across all runs.
A high likelihood tree from run 1 is shown in Fig. 6; each node contains the (predictor,
threshold) which created the node split, the number of sample individuals in the node, and the
posterior predictive probability of 3-year survival for the node subpopulation. Several clinical
variables,particularlydisease-freeintervalbutalsoage,grade,anddebulkingstatus,appearintop
trees along with a group of metagene predictors. The speciﬁc metagene predictors vary with each
run but by comparing the key metagenes across runs we do ﬁnd genes which appear frequently
and for which potentially very relevant biological connections can be made; see Section 5.4
for a discussion of several such connections. A summary of the predictors which appear in the
top trees from run 4 is presented in a tree matrix plot in Fig. 7. For each predictor the sum
of the probabilities of the trees in which the predictor appears is shown on the horizontal axis;
this serves as a simple numeric assessment of the relative importance of these variables in the
prediction of survival.
Fig. 8 shows a snapshot of predictions of the probability of 3-year survival from run 6. In
this example many of the uncertainty intervals are large which reﬂects the small sample size and
heterogeneity of the sample population.
A posterior sample of predictions for each individual can be generated via Monte Carlo
sampling of the µz,τj and computing the corresponding values of P(y? > t | x?). This provides
simulation-based posterior means and uncertainty intervals which are critical in determining
the importance of a prediction in clinical decision making. To illustrate this, we selected
three individuals from the data set and displayed their predicted survival curves from the CG
models in the panels of Fig. 9. These curves extend over several years and include uncertainty
intervals at certain time points. Cases 2424 and 1451 are examples where the conﬁdence
in prediction, either of short-term (#2424) or long-term survival (#1451), is quite high, as
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Fig. 7. Summary of split variables and corresponding split levels for top trees in run 4. Vertical axis shows tree indices
and tree weights; horizontal axis shows each split variable and sum of probabilities of trees in which variable occurs
(importance weight).
Fig. 8. Predictions of 3-year survival for validation samples generated by averaging over trees.
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evidenced by the narrow uncertainty bars. Case #2424 was an older patient whose tumor
was suboptimally debulked and whose disease remained stable after platinum chemotherapy;
she had no disease-free interval and survived for 16 months. Case #1451 was also an older
patient whose tumor was suboptimally debulked but whose disease responded to platinum
chemotherapy; her disease-free interval was 28 months and her overall survival time was 132
months. In contrast, the predictive survival curves for other cases are highly uncertain. These
are cases where the number of patients with similar characteristics is very small or there is
conﬂict among the clinico-genomic predictors and hence disagreement among tree outcomes.
Case #1774 was an older patient who was optimally debulked and whose disease responded to
platinum therapy, which would classify her as clinically low risk. Her disease-free interval was
more than 10 months and her overall survival time was 22 months. Upon closer examination
it was revealed that she had values on key metagenes that conﬂicted with her low-risk clinical
assessment. The short-term predictions for case #1774 were the result of her value for metagene
357; on further inspection we discovered that this metagene contained a probe for the gene
TNK2 (alias ACK1) for which this patient had an extremely high value (see Section 5.4 for
further discussion of this ﬁnding). It seems evident that the metagene predictors are capturing
information in the genomic predictors which may or may not be reﬂected in the clinical
predictors. In such cases it is important that the overall prediction summary recognizes and
reﬂects this uncertainty and that models be open to investigation so that such results can be
explored.
In some cases the results using clinical data alone are better than those using both clinical and
genomic data (see, for example, Run 3 in Table 2). We suppose that this is due to heterogeneity in
the patient subsamples, as no speciﬁc gene or metagene was found to be relevant to all samples.
It is possible that the clinico-genomic trees could be improved further in these cases by altering
the hyperparameter values, such as the Bayes factor threshold, but given the limited amount of
data available we chose not to vary the parameter settings across different runs. Given more data
the speciﬁc tuning of model parameters can be explored in more depth.
5.4. Biological relevance
As mentioned in Section 5.3 the metagene predictors vary with each run but we did identify
genes which appear in the key metagenes of several runs and for which potentially very
relevant biological connections can be made. This demonstrates the power of our approach
for exploratory data analysis as well as prediction. We mention a few examples here; a more
complete list of metagenes which appeared in predictive trees and their component genes are
given in Table 3 [65].
First, the tree in Fig. 6 includes metagene (Mg) 254 as a split variable. This metagene
includes multiple probes for gene CYP1B1; the enzyme encoded by this gene is involved
in androgen metabolism and the metabolism of various procarcinogens. CYP1B1 has been
associated with risk of endometrial cancer [55] and breast and ovarian cancer as a downstream
target of BRCA1 expression during xenobiotic stress [36]. Second, the key variables which
appear in the CG trees from run 4 appear in Fig. 7; we will focus on Mg 127 and Mg 178.
Mg 127 contains Krit1 as a component gene; Krit1 has been shown to interact with a proposed
tumor suppressor and may act as an antagonist of the oncogene Ras. The Krit1 cDNA has
been mapped to a chromosomal location frequently deleted or ampliﬁed in multiple forms of
cancer [59]. Mg 178 contains NR2F2 (COUP-TFII), a gene which encodes for a transcription
factor shown to be critical for normal female reproduction in mice [64] and menstrual cycling in
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Fig. 9. Predicted disease-free survival curves with uncertainty intervals at chosen time points for three individuals.
The ROC cutoff (dashed line) for classiﬁcation as short-term or long-term survivor and the prediction of survival at
3 years (blue number on the y-axis) are identiﬁed. The actual survival time is marked with an arrow on the x-axis. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.).
human ovaries [56]. This cluster also includes TCF7L2 (TCF-4) which plays a role in the beta
catenin-Wnt signaling pathway, a pathway considered one of the key developmental and growth
regulatory mechanisms of the cell [22]. In particular the regulation of Cyclin D1 by Rac1 is beta-
catenin/TCF-dependent [20]; Cyclin D1 is a Wnt target gene which alters cell cycle progression
and in which mutations, ampliﬁcation and overexpression are observed frequently in a variety of
tumors and may contribute to tumorigenesis. Finally, NF-YB is also found in this cluster; NF-
YB encodes a transcription factor necessary for the negative regulation of Chk2 expression by
p53 [42]. This process is critical for the control of cell cycle progression in response to DNA
damage. NF-YB also interacts with the oncogenes c-Myc, pRb, and p53 to control expression of
the PDGF beta-receptor which is tightly regulated during a normal cell cycle [68].
The examination of subjects whose predictions improve signiﬁcantly upon the inclusion
of genomic data can also yield potentially informative genes. The ACK1 gene mentioned in
Section 5.3 was discovered by this strategy. The ampliﬁcation of the ACK1 gene in primary
tumors has been shown to correlate with poor prognosis and the overexpression of ACK1 in
cancer cell lines can increase the invasive phenotype of these cells both in vitro and in vivo [69].
In our data set the expression of ACK1 was found to be negatively correlated (not signiﬁcantly)
with survival; however, in the complete data set of 119 individuals this correlation was signiﬁcant
(see Fig. 10). These ﬁndings support the theory of Bernards and Weinberg [4] that genetic
alterations acquired early in the process of tumor development may drive primary tumor growth
and determine metastatic potential.
The identiﬁcation of multiple genes with predictive ability and potential biological relevance
to tumor development, reﬂective of the heterogeneity of the patient sample and the complexity
of the underlying disease, is a key ﬁnding and suggestive of plausible directions for biological
investigation.
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Fig. 10. Relationship of ACK1 expression and survival; all 119 patients.
6. Discussion
We have presented a Bayesian approach to tree analysis in the speciﬁc context of a survival
time response and both clinical and genomic predictors. Survival times are assumed to follow
a Weibull distribution and tree construction is based on forward selection where a split on a
(predictor,threshold) pair is performed if the evidence for or against a difference in survival
distributions between the resulting subgroups is signiﬁcant, as assessed by the associated Bayes
factor. By averaging predictions across trees with the relative likelihood values as weights
we will tend to improve predictions by respecting, and properly accounting for, tree model
uncertainty [25].
We note that although averaging predictions across trees does improve model performance,
it also decreases the interpretability of the model. This is an important trade-off: predictive
ability versus model interpretability. We advocate model averaging because of its improved
predictions and because in high-dimensional data settings model uncertainty can be substantial.
Bybuildingmultipletreemodelswecanexplorethecovariatespaceandattempttoaddressmodel
uncertainty.
We understand that in the interpretation of tree models (in terms of prediction accuracy as
well as variable selection) it is important that the parameter estimates be unbiased. This has been
stressedintherecenttreeliterature,e.g.,[41,40,27].Ourmodelsarenotunbiasedinthesensethat
variables with more splitting values are more likely to be selected in model building. To address
this bias we have chosen a metric for model accuracy based on predictive accuracy. This metric
will help us to identify and remove from consideration ‘ﬂuke’ models which ﬁt the data well
but have poor predictive performance. We concede that this approach is not computationally
efﬁcient but it does allow for model exploration which is critical at this point of our analysis.
Of course as more data is collected we suspect that computational expense will increase but
model uncertainty will decrease, at which point we may focus on averaging over fewer models
or employing an alternate method which places more emphasis on unbiasedness and model
estimation.
We implemented our survival tree modeling in the analysis of pilot data from a study of
advanced stage ovarian cancer. Multiple, related patterns of gene expression in combination
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with clinical data provided strong and predictively valid associations with survival. The models
delivered predictive survival assessments together with measures of uncertainty about the
predictions. As a result of tree spawning and model averaging these measures of uncertainty
reﬂected within-tree variability as well as the variability resulting from the sensitivity of
the Bayes factor to speciﬁc predictor choices and small changes in threshold values. An
examination of genes which demonstrate predictive ability across various training and test sets
revealed several genes with biologically plausible relevance to carcinogenesis, warranting further
investigation.
We chose to use a conjugate Gamma prior in our analysis although a non-informative prior,
such as a Jeffreys’ prior, could have been employed. The Jeffreys’ prior is a Gamma(a,b) where
a = b = 0 [53]. This prior would put relatively more weight on extreme survival values;
we felt it was more appropriate to choose values of a and b based on the observed survival
times. However for large sample sizes there should be little difference in the results under
the conjugate versus the Jeffreys’ prior. Thus we expect little difference in the results from
each prior at the root and upper level nodes. In small sample sizes, e.g., lower level nodes,
we may see some differences in the models but the prior parameters are being updated by
previous tree splits which will mitigate any differences. These suppositions were conﬁrmed
when we repeated a subset of the simulations from Section 4 using the Jeffreys’ prior. The
MIE values increased under the Jeffreys’ prior relative to the results under the conjugate prior,
and the ability to capture the correct model decreased, but qualitatively the results did not
change.
In anticipation of future studies we intend to perform further comparisons with existing
methods [27,33] and further simulations to examine the impact of tuning parameters and prior
assumptions on model performance. Our current approach to missing values is to perform
imputation prior to modeling; however, we are considering adjusting our method to deal
with missing values as these are common in realistic data analysis contexts. In this study
our models were built on 6400 genes and 310 metagenes; it is possible that information
from normal tissue samples could be employed to perform further variable selection. Finally,
although some progress has been made in developing stochastic simulation methods for
Bayesian trees [54] the topic remains a very challenging research area, both conceptually
and computationally, particularly in the context of more than a few predictors. We believe
that in problems where the numbers of predictors is very large, properly addressing the
issue of stochastic search will involve the development of a formal, conceptual foundation
before making them practicable. The development of such ideas is a focus of our current
research.
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Appendix
Table 3
Genes which appear in Weibull tree models in at least 3 of the 10 training runs
Key genes
Runs Cluster Affy probe ID NCBI entrez
gene
Gene ontology
1, 4, 5, 9 468, 185, 25,
422
213158 at Unknown gene
1, 5, 8 468, 25, 473 205383 s at ZBTB20 Physiological process
1, 4, 10 378, 148, 295 207571 x at C1orf38
1, 4, 10 378, 148, 295 210785 s at C1orf38
1, 4, 10 195, 441, 135 201486 at RCN2
1, 4, 10 195, 441, 135 209085 x at RFC1 DNA-dependent DNA
replication/DNA metabolism
Physiological process
4, 6, 10 441, 210, 241 213838 at NOL7
3, 7, 10 448, 451, 241 200958 s at SDCBP Substrate-bound cell migration/cell
extension
Physiological process
2, 4, 5, 7 161, 309, 475,
303
213705 at MAT2A Physiological process
2, 5, 9 161, 475, 213 219437 s at ANKRD11
2, 4, 7 161, 309, 303 202028 s at RPL38 Physiological process
2, 4, 7 161, 309, 303 208120 x at Unknown gene
2, 4, 7 161, 309, 303 210686 x at SLC25A16 Physiological process
2, 4, 7 161, 309, 303 211454 x at Unknown gene
2, 4, 7 161, 309, 303 212044 s at RPL27A Protein
biosynthesis/macromolecule
biosynthesis
Physiological process
2, 4, 7 161, 309, 303 213736 at COX5B Physiological process
2, 4, 7 161, 309, 303 214001 x at RPS10 Physiological process
2, 4, 7 161, 309, 303 214041 x at RPL37A Protein
biosynthesis/macromolecule
biosynthesis
Physiological process
2, 4, 7 161, 309, 303 221943 x at RPL38 Physiological process
2, 4, 7 161, 309, 303 218808 at DALRD3 Protein
biosynthesis/macromolecule
biosynthesis arginyl-tRNA
aminoacylation
Physiological process
4, 7, 9 309, 487, 335 208141 s at HLRC1
4, 7, 9 309, 487, 335 216180 s at SYNJ2 Physiological process
5, 9, 10 404, 335, 313 208868 s at GABARAPL1
2, 4, 9 105, 185, 422 218962 s at FLJ13576
2, 4, 8 105, 185, 403 216713 at KRIT1
2, 4, 8 105, 226, 403 34041 i at Unknown gene
2, 4, 8 105, 226, 403 221596 s at DKFZP564O0523
(continued on next page)
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Table 3 (continued)
Key genes
Runs Cluster Affy probe ID NCBI entrez
gene
Gene ontology
2, 3, 7 446, 23, 265 203277 at DFFA DNA fragmentation during
apoptosis disassembly of cell
structures during apoptosis
Apoptotic nuclear changes
DNA catabolism/DNA metabolism
Physiological process
2, 3, 9 446, 23, 357 201155 s at MFN2
1, 2, 9 378, 446, 357 221269 s at SH3BGRL3
4, 5, 9 409, 25, 100 209120 at NR2F2 Physiological process
4, 5, 9 409, 25, 100 209121 x at NR2F2 Physiological process
4, 5, 9 409, 25, 100 215073 s at NR2F2 Physiological process
4, 5, 7 409, 25, 449 212761 at TCF7L2 Physiological process
1, 3, 10 373, 82, 285 202435 at Unknown gene
1, 3, 10 373, 82, 285 202436 at Unknown gene
1, 3, 10 373, 82, 285 202437 at Unknown gene
1, 3, 10 282, 82, 282 209146 at SC4MOL Physiological process
4, 6, 10 226, 49, 473 202375 at SEC24D Physiological process
4, 6, 10 226, 99, 473 209501 at CDR2
4, 6, 9 51, 466, 53 212205 at H2AFV DNA metabolism
Physiological process
4, 6, 9 409, 466, 299 218127 at NF-YB Physiological process
4, 6, 7 312, 490, 434 213246 at C14orf109
3, 5, 10 121, 55, 486 208070 s at REV3L DNA-dependent DNA
replication/DNA metabolism
Physiological process
1, 5, 9 154, 97, 227 209170 s at GPM6B
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